Cargando…
Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM
Patients with rheumatoid arthritis (RA) may experience residual pain and functional impairment despite good control of disease activity. This study compared improvements in pain and physical function in patients with well-controlled RA after 24 weeks’ treatment with baricitinib, adalimumab or placeb...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6780319/ https://www.ncbi.nlm.nih.gov/pubmed/31492040 http://dx.doi.org/10.3390/jcm8091394 |
_version_ | 1783457104997122048 |
---|---|
author | Fautrel, Bruno Kirkham, Bruce Pope, Janet E. Takeuchi, Tsutomu Gaich, Carol Quebe, Amanda Zhu, Baojin de la Torre, Inmaculada De Leonardis, Francesco Taylor, Peter C. |
author_facet | Fautrel, Bruno Kirkham, Bruce Pope, Janet E. Takeuchi, Tsutomu Gaich, Carol Quebe, Amanda Zhu, Baojin de la Torre, Inmaculada De Leonardis, Francesco Taylor, Peter C. |
author_sort | Fautrel, Bruno |
collection | PubMed |
description | Patients with rheumatoid arthritis (RA) may experience residual pain and functional impairment despite good control of disease activity. This study compared improvements in pain and physical function in patients with well-controlled RA after 24 weeks’ treatment with baricitinib, adalimumab or placebo in the 52-week RA-BEAM phase III study. Adults with active RA and inadequate response to methotrexate received baricitinib 4 mg once daily, adalimumab 40 mg every two weeks or placebo, with background methotrexate. Patients (N = 1010) were categorised as in remission, in remission or low disease activity, or not in remission or low disease activity at week 24. For patients in remission or low disease activity (n = 310), improvements in mean pain and physical function scores at week 24 were significantly greater with baricitinib than placebo (p < 0.001 and p < 0.01, respectively) and adalimumab (p < 0.05 for both). For both outcomes, differences between adalimumab and placebo were not significant. The proportions of patients in remission or low disease activity with minimal or no pain and with normalised physical function were numerically greater with baricitinib than placebo. Baricitinib 4 mg once daily provided enhanced improvement in pain and physical function in patients with well-controlled RA, suggesting it may produce effects beyond immunomodulation. |
format | Online Article Text |
id | pubmed-6780319 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-67803192019-10-30 Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM Fautrel, Bruno Kirkham, Bruce Pope, Janet E. Takeuchi, Tsutomu Gaich, Carol Quebe, Amanda Zhu, Baojin de la Torre, Inmaculada De Leonardis, Francesco Taylor, Peter C. J Clin Med Article Patients with rheumatoid arthritis (RA) may experience residual pain and functional impairment despite good control of disease activity. This study compared improvements in pain and physical function in patients with well-controlled RA after 24 weeks’ treatment with baricitinib, adalimumab or placebo in the 52-week RA-BEAM phase III study. Adults with active RA and inadequate response to methotrexate received baricitinib 4 mg once daily, adalimumab 40 mg every two weeks or placebo, with background methotrexate. Patients (N = 1010) were categorised as in remission, in remission or low disease activity, or not in remission or low disease activity at week 24. For patients in remission or low disease activity (n = 310), improvements in mean pain and physical function scores at week 24 were significantly greater with baricitinib than placebo (p < 0.001 and p < 0.01, respectively) and adalimumab (p < 0.05 for both). For both outcomes, differences between adalimumab and placebo were not significant. The proportions of patients in remission or low disease activity with minimal or no pain and with normalised physical function were numerically greater with baricitinib than placebo. Baricitinib 4 mg once daily provided enhanced improvement in pain and physical function in patients with well-controlled RA, suggesting it may produce effects beyond immunomodulation. MDPI 2019-09-05 /pmc/articles/PMC6780319/ /pubmed/31492040 http://dx.doi.org/10.3390/jcm8091394 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Fautrel, Bruno Kirkham, Bruce Pope, Janet E. Takeuchi, Tsutomu Gaich, Carol Quebe, Amanda Zhu, Baojin de la Torre, Inmaculada De Leonardis, Francesco Taylor, Peter C. Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM |
title | Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM |
title_full | Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM |
title_fullStr | Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM |
title_full_unstemmed | Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM |
title_short | Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM |
title_sort | effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: exploratory analyses from ra-beam |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6780319/ https://www.ncbi.nlm.nih.gov/pubmed/31492040 http://dx.doi.org/10.3390/jcm8091394 |
work_keys_str_mv | AT fautrelbruno effectofbaricitinibandadalimumabinreducingpainandimprovingfunctioninpatientswithrheumatoidarthritisinlowdiseaseactivityexploratoryanalysesfromrabeam AT kirkhambruce effectofbaricitinibandadalimumabinreducingpainandimprovingfunctioninpatientswithrheumatoidarthritisinlowdiseaseactivityexploratoryanalysesfromrabeam AT popejanete effectofbaricitinibandadalimumabinreducingpainandimprovingfunctioninpatientswithrheumatoidarthritisinlowdiseaseactivityexploratoryanalysesfromrabeam AT takeuchitsutomu effectofbaricitinibandadalimumabinreducingpainandimprovingfunctioninpatientswithrheumatoidarthritisinlowdiseaseactivityexploratoryanalysesfromrabeam AT gaichcarol effectofbaricitinibandadalimumabinreducingpainandimprovingfunctioninpatientswithrheumatoidarthritisinlowdiseaseactivityexploratoryanalysesfromrabeam AT quebeamanda effectofbaricitinibandadalimumabinreducingpainandimprovingfunctioninpatientswithrheumatoidarthritisinlowdiseaseactivityexploratoryanalysesfromrabeam AT zhubaojin effectofbaricitinibandadalimumabinreducingpainandimprovingfunctioninpatientswithrheumatoidarthritisinlowdiseaseactivityexploratoryanalysesfromrabeam AT delatorreinmaculada effectofbaricitinibandadalimumabinreducingpainandimprovingfunctioninpatientswithrheumatoidarthritisinlowdiseaseactivityexploratoryanalysesfromrabeam AT deleonardisfrancesco effectofbaricitinibandadalimumabinreducingpainandimprovingfunctioninpatientswithrheumatoidarthritisinlowdiseaseactivityexploratoryanalysesfromrabeam AT taylorpeterc effectofbaricitinibandadalimumabinreducingpainandimprovingfunctioninpatientswithrheumatoidarthritisinlowdiseaseactivityexploratoryanalysesfromrabeam |